Skip to main content
Top
Published in: European Journal of Pediatrics 4/2021

Open Access 01-04-2021 | Cystic Fibrosis | Original Article

Implementing a tracking system for confirmatory diagnostic results after positive newborn screening for cystic fibrosis—implications for process quality and patient care

Authors: Gwendolyn Gramer, Inken Brockow, Christiane Labitzke, Junmin Fang-Hoffmann, Andreas Beivers, Patrik Feyh, Georg F. Hoffmann, Uta Nennstiel, Olaf Sommerburg

Published in: European Journal of Pediatrics | Issue 4/2021

Login to get access

Abstract

Newborn screening for cystic fibrosis (CF-NBS) was introduced in Germany in 2016. Currently, systematic follow-up of positive CF-NBS results is not implemented or reimbursed in the NBS program. We investigated results of confirmatory testing over 24 months after implementation of CF-NBS for a large German NBS center before and after introduction of an active tracking system and performed a cost calculation for tracking. Results are compared with the federal state of Bavaria, where a centralized tracking system has been in place for many years. At the NBS center, 244 of 281,907 children had a positive CF-NBS result requiring diagnostic confirmation. Before implementation of a telephone tracking system, only 43% of confirmatory results were returned despite repeated written requests. The consecutive strategy including telephone tracking led to an increase of resolved cases to 84%. However, the centralized tracking system in Bavaria, assigning children with positive CF-NBS directly to a responsible CF-center, resolved 99% of cases. The calculated additional cost for a tracking system in Germany including telephone tracking is 1.20€ per newborn screened.
Conclusion: The implementation of a tracking system achieves a distinct improvement in CF-NBS with justifiable costs. The effect can be limited by absence of centralized organization of confirmatory testing.
What is Known:
• Newborn screening for cystic fibrosis (CF-NBS) has been performed for many years in several countries worldwide
• While many studies have focused on different CF-NBS strategies, the organization of confirmatory testing and process quality concerning returned information to the NBS center has so far received less attention.
What is New:
• The implementation of an active tracking system achieves a distinct improvement of clarified cases after positive CF-NBS with justifiable costs.
• The effect of a tracking system can be limited by the absence of a centralized organization of confirmatory testing.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab KO, Tacke U, Trefz FK, Mengel E, Wendel U, Leichsenring M, Burgard P, Hoffmann GF (2011) Efficacy and outcome of expanded newborn screening for metabolic diseases-report of 10 years from South-West Germany. Orphanet J Rare Dis 6:44CrossRef Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab KO, Tacke U, Trefz FK, Mengel E, Wendel U, Leichsenring M, Burgard P, Hoffmann GF (2011) Efficacy and outcome of expanded newborn screening for metabolic diseases-report of 10 years from South-West Germany. Orphanet J Rare Dis 6:44CrossRef
2.
go back to reference Wilcken B, Haas M, Joy P, Wiley V, Bowling F, Carpenter K, Christodoulou J, Cowley D, Ellaway C, Fletcher J, Kirk EP, Lewis B, McGill J, Peters H, Pitt J, Ranieri E, Yaplito-Lee J, Boneh A (2009) Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 124:e241–e248CrossRef Wilcken B, Haas M, Joy P, Wiley V, Bowling F, Carpenter K, Christodoulou J, Cowley D, Ellaway C, Fletcher J, Kirk EP, Lewis B, McGill J, Peters H, Pitt J, Ranieri E, Yaplito-Lee J, Boneh A (2009) Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 124:e241–e248CrossRef
3.
go back to reference Barben J, Castellani C, Dankert-Roelse J, Gartner S, Kashirskaya N, Linnane B, Mayell S, Munck A, Sands D, Sommerburg O, Pybus S, Winters V, Southern KW (2017) The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 16:207–213CrossRef Barben J, Castellani C, Dankert-Roelse J, Gartner S, Kashirskaya N, Linnane B, Mayell S, Munck A, Sands D, Sommerburg O, Pybus S, Winters V, Southern KW (2017) The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 16:207–213CrossRef
5.
go back to reference Kinder-Richtlinie (2017) Gemeinsamer Bundesausschuss der Ärzte und Krankenkassen (2017). Richtlinie des Gemeinsamen Bundesausschusses über die Früherkennung von Krankheiten bei Kindern (Kinder-Richtlinie) in der Fassung vom 18. Juni 2015. Zuletzt geändert am 19. Oktober 2017, in Kraft getreten am 16. März 2018. https://www.g-ba.de/richtlinien/historie/1537/ Kinder-Richtlinie (2017) Gemeinsamer Bundesausschuss der Ärzte und Krankenkassen (2017). Richtlinie des Gemeinsamen Bundesausschusses über die Früherkennung von Krankheiten bei Kindern (Kinder-Richtlinie) in der Fassung vom 18. Juni 2015. Zuletzt geändert am 19. Oktober 2017, in Kraft getreten am 16. März 2018. https://​www.​g-ba.​de/​richtlinien/​historie/​1537/​
6.
go back to reference Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd, Cystic Fibrosis F (2008) Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153:S4–S14CrossRef Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd, Cystic Fibrosis F (2008) Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153:S4–S14CrossRef
8.
go back to reference Sommerburg O, Hammermann J, Lindner M, Stahl M, Muckenthaler M, Kohlmueller D, Happich M, Kulozik AE, Stopsack M, Gahr M, Hoffmann GF, Mall MA (2015) Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany. Pediatr Pulmonol 50:655–664CrossRef Sommerburg O, Hammermann J, Lindner M, Stahl M, Muckenthaler M, Kohlmueller D, Happich M, Kulozik AE, Stopsack M, Gahr M, Hoffmann GF, Mall MA (2015) Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany. Pediatr Pulmonol 50:655–664CrossRef
9.
go back to reference Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodkova P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P (2018) ECFS best practice guidelines: the 2018 revision. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 17:153–178CrossRef Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodkova P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P (2018) ECFS best practice guidelines: the 2018 revision. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 17:153–178CrossRef
10.
go back to reference Rueegg CS, Kuehni CE, Gallati S, Baumgartner M, Torresani T, Barben J (2013) One-year evaluation of a neonatal screening program for cystic fibrosis in Switzerland. Deut Arzteblatt Int 110:356–363 Rueegg CS, Kuehni CE, Gallati S, Baumgartner M, Torresani T, Barben J (2013) One-year evaluation of a neonatal screening program for cystic fibrosis in Switzerland. Deut Arzteblatt Int 110:356–363
11.
go back to reference Brockow I, Nennstiel U (2019) Parents' experience with positive newborn screening results for cystic fibrosis. Eur J Pediatr 178:803–809CrossRef Brockow I, Nennstiel U (2019) Parents' experience with positive newborn screening results for cystic fibrosis. Eur J Pediatr 178:803–809CrossRef
13.
go back to reference Gramer G, Nennstiel-Ratzel U, Hoffmann GF (2018) 50 Jahre Neugeborenenscreening in Deutschland - Bisherige Ergebnisse und zukünftige Herausforderungen (50 years of newborn screening in Germany. Achievements and future challenges). Monatsschr Kinderheilkd 166:987–993 Gramer G, Nennstiel-Ratzel U, Hoffmann GF (2018) 50 Jahre Neugeborenenscreening in Deutschland - Bisherige Ergebnisse und zukünftige Herausforderungen (50 years of newborn screening in Germany. Achievements and future challenges). Monatsschr Kinderheilkd 166:987–993
14.
go back to reference Munck A, Mayell SJ, Winters V, Shawcross A, Derichs N, Parad R, Barben J, Southern KW (2015) Cystic fibrosis screen positive, inconclusive diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cystic Fibros 14:706–713CrossRef Munck A, Mayell SJ, Winters V, Shawcross A, Derichs N, Parad R, Barben J, Southern KW (2015) Cystic fibrosis screen positive, inconclusive diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cystic Fibros 14:706–713CrossRef
15.
go back to reference Nennstiel-Ratzel U, Lüders A, Blankenstein O (2015) Newborn screening: a prime example for effective secondary prevention. Bundesgesundheitsbl, Gesundheitsforsch, Gesundheitsschutz 58:139–145CrossRef Nennstiel-Ratzel U, Lüders A, Blankenstein O (2015) Newborn screening: a prime example for effective secondary prevention. Bundesgesundheitsbl, Gesundheitsforsch, Gesundheitsschutz 58:139–145CrossRef
16.
go back to reference Brockow I, Kummer P, Liebl B, Nennstiel-Ratzel U (2011) Universal newborn hearing screening (UNHS): is it possible to successfully implement it nationwide? Gesundheitswesen 73:477–482CrossRef Brockow I, Kummer P, Liebl B, Nennstiel-Ratzel U (2011) Universal newborn hearing screening (UNHS): is it possible to successfully implement it nationwide? Gesundheitswesen 73:477–482CrossRef
17.
go back to reference Gramer G, Hoffmann GF, Nennstiel-Ratzel U (2015) Das erweiterte Neugeborenenscreening - Erfolge und neue Herausforderungen. Springer Essentials. Springer Fachmedien Wiesbaden Gramer G, Hoffmann GF, Nennstiel-Ratzel U (2015) Das erweiterte Neugeborenenscreening - Erfolge und neue Herausforderungen. Springer Essentials. Springer Fachmedien Wiesbaden
18.
go back to reference Schmidt M, Werbrouck A, Verhaeghe N, De Wachter E, Simoens S, Annemans L, Putman K (2018) Strategies for newborn screening for cystic fibrosis: a systematic review of health economic evaluations. J Cystic Fibros 17:306–315CrossRef Schmidt M, Werbrouck A, Verhaeghe N, De Wachter E, Simoens S, Annemans L, Putman K (2018) Strategies for newborn screening for cystic fibrosis: a systematic review of health economic evaluations. J Cystic Fibros 17:306–315CrossRef
19.
go back to reference Sims EJ, Mugford M, Clark A, Aitken D, McCormick J, Mehta G, Mehta A, Committee UKCFDS (2007) Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 369:1187–1195CrossRef Sims EJ, Mugford M, Clark A, Aitken D, McCormick J, Mehta G, Mehta A, Committee UKCFDS (2007) Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 369:1187–1195CrossRef
20.
go back to reference Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, Demmer L, Eaton RB, Greenstein R, Korson M, Larson C, Marsden D, Msall M, Naylor EW, Pueschel S, Seashore M, Shih VE, Levy HL (2003) Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 290:2564–2572CrossRef Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, Demmer L, Eaton RB, Greenstein R, Korson M, Larson C, Marsden D, Msall M, Naylor EW, Pueschel S, Seashore M, Shih VE, Levy HL (2003) Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 290:2564–2572CrossRef
Metadata
Title
Implementing a tracking system for confirmatory diagnostic results after positive newborn screening for cystic fibrosis—implications for process quality and patient care
Authors
Gwendolyn Gramer
Inken Brockow
Christiane Labitzke
Junmin Fang-Hoffmann
Andreas Beivers
Patrik Feyh
Georg F. Hoffmann
Uta Nennstiel
Olaf Sommerburg
Publication date
01-04-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics / Issue 4/2021
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-020-03849-4

Other articles of this Issue 4/2021

European Journal of Pediatrics 4/2021 Go to the issue